FilingSEC EDGAR8-K
PDS Biotech to Host KOL Event to Discuss PDS0301 Clinical Results
· SEC accepted
StagePhase 2
Filing content
PDS Biotech will host a virtual KOL event on October 15 to discuss Phase 2 clinical outcomes of PDS0301 for metastatic colorectal cancer with an NCI investigator.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…